These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15176002)

  • 1. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
    McArthur G
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for dermatofibrosarcoma protuberans.
    Abrams TA; Schuetze SM
    Curr Oncol Rep; 2006 Jul; 8(4):291-6. PubMed ID: 17254529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermatofibrosarcoma protuberans: recent clinical progress.
    McArthur G
    Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
    Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
    Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment options in dermatofibrosarcoma protuberans.
    Lemm D; Mügge LO; Mentzel T; Höffken K
    J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
    Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
    Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
    Johnson-Jahangir H; Sherman W; Ratner D
    J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
    Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
    Labropoulos SV; Fletcher JA; Oliveira AM; Papadopoulos S; Razis ED
    Anticancer Drugs; 2005 Apr; 16(4):461-6. PubMed ID: 15746584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results.
    Malhotra B; Schuetze SM
    Curr Opin Oncol; 2012 Jul; 24(4):419-24. PubMed ID: 22510939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dermatofibrosarcoma protuberans].
    Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
    Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition.
    Mattox AK; Mehta AI; Grossi PM; Cummings TJ; Adamson DC
    J Neurosurg; 2010 May; 112(5):965-77. PubMed ID: 19681684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
    Shimizu A; O'Brien KP; Sjöblom T; Pietras K; Buchdunger E; Collins VP; Heldin CH; Dumanski JP; Ostman A
    Cancer Res; 1999 Aug; 59(15):3719-23. PubMed ID: 10446987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
    Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
    J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
    Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH
    Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
    Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
    Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
    J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors.
    Kallini JR; Khachemoune A
    J Drugs Dermatol; 2014 Dec; 13(12):1474-7. PubMed ID: 25607791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.